Ganetespib (STA-9090)

Catalog No.S1159

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Price Stock Quantity  
USD 302 In stock
USD 270 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Ganetespib (STA-9090) Chemical Structure

Ganetespib (STA-9090) Chemical Structure
Molecular Weight: 364.4

Validation & Quality Control

2 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Ganetespib (STA-9090) is available in the following compound libraries:

HSP (e.g. HSP90) Inhibitors with Unique Features

  • Selective HSP90 Inhibitor

    NVP-BEP800 HSP90β-selective, IC50=58 nM.

  • Most Potent HSP90 Inhibitor

    KW-2478 HSP90, IC50=3.8 nM.

  • HSP90 Inhibitor in Clinical Trial

    17-AAG (Tanespimycin) Phase III for Gastrointestinal Stromal Tumors.

  • Newest HSP90 Inhibitor

    XL888 ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Product Information

  • Compare HSP (e.g. HSP90) Inhibitors
    Compare HSP (e.g. HSP90) Products
  • Research Area

Product Description

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets HSP90 [1]
(OSA 8 cells)
IC50 4 nM
In vitro The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HL60NWTMPXhxSXCxcITvd4l{KEG|c3H5NGHvN24{OC96MD:xOVAwOjVyIH7NMX[yOE81QC95MjDoNXTHZ3NlcW6mdXPld{Bld3OnIHTldIVv\GGwdDDpcoR2[3Srb36gc4Yh[XCxcITvd4l{MkDxNlU5QDJ3NUC=
MV411NG\tPW9CeG:ydH;zbZMhSXO|YYm=M13t[|MxNzhyL{G1NE8zPTBibl2=MmrPNlQwPDhxN{KgbC=>NFPZXHdqdmS3Y3XzJIRwe2ViZHXw[Y5l[W62IHnu[JVkfGmxbjDv[kBieG:ydH;zbZM>NIf4e|czPTh6MkW1NC=>
MGC-803MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NELGVWIxNjFvMUCwNEBvVQ>?NHXET2E4OiCqM4jXW4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?MVeyOVU6ODhyNR?=
SGC-7901MljDR4VtdCCYaXHibYxqfHliQYPzZZk>M4Wy[lAvOS1zMECwJI5ONHjqSlg4OiCqM3nhc4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?M4HRe|I2PTlyOEC1
MKN-28MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NH\INVMxNjFvMUCwNEBvVQ>?M1vXWlczKGh?MYHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6M1HwOFI2PTlyOEC1
MGC-803M325dmZ2dmO2aX;uJGF{e2G7NYH2T2ZFOC5zLUGwNFAhdk1?M4[zZ|I1KGh?NGrjPHVqdmS3Y3XzJGczN01iY3XscE1kgWOuZTDhdpJme3R?M{C2elI2PTlyOEC1
HCT-116NUS4VVE3TnWwY4Tpc44hSXO|YYm=M1HvNlUxdk1?MYiyOEBpMlTQSG1UVw>?MnXRbY5lfWOnZDDHNE9IOSCjcoLld5Q>M3;UflI2OjFyN{m0
HT-29MnzHSpVv[3Srb36gRZN{[Xl?M1PGVFUxdk1?NFzNZ4gzPCCqNXeyS|J5TE2VTx?=NIroWFBqdmS3Y3XkJGcxN0dzIHHydoV{fA>?NFi0VVgzPTJzMEe5OC=>
SCC25M1m0UWN6fG:6aXPpeJkhSXO|YYm=NVrYdHFpOTBxNUCgcm0>MnyzNlQhcA>?M2qyXIRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDk[ZBmdmSnboTsfS=>Mn73NlUzODV2M{C=
FUDAM{jpNWN6fG:6aXPpeJkhSXO|YYm=NGj6[|kyOC93MDDuUS=>NYrR[|dCOjRiaB?=MV\k[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm=NWrpXmF[OjV{MEW0N|A>
Detroit562NVzQTVM4S3m2b4jpZ4l1gSCDc4PhfS=>NEjrVWIyOC93MDDuUS=>MUmyOEBpMYjk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm=NUfDUG8xOjV{MEW0N|A>
CAL27Mn:4R5l1d3irY3n0fUBCe3OjeR?=NYTNTGlmOTBxNUCgcm0>MWiyOEBpMlz2[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5MVqyOVIxPTR|MB?=
DSH1NFvwVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\0XGlEPTB;NjDuUS=>NXHWcVJsOjR5OES4N|k>
SW-1710NHX6TJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXJTWM2OD14IH7NM4LQNlI1Pzh2OEO5
T24NHqwTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTdibl2=NHPHVnUzPDd6NEizPS=>
RT112MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTlibl2=M4PERVI1Pzh2OEO5
639-VM3y0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\mTWM2OD1zMDDuUS=>NV;mPVZ4OjR5OES4N|k>
SCaBERNV76[GpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M373SGlEPTB;MUCgcm0>MU[yOFc5PDh|OR?=
BFTCNV36SmsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M176NWlEPTB;MUegcm0>NYPFR3htOjR5OES4N|k>
J82NHnsXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\BZWlEPTB;MUigcm0>NHzZT20zPDd6NEizPS=>
HT-1376NFXob3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTJzIH7NNXr5bHlbOjR5OES4N|k>
647-VMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHINXlKSzVyPUK3JI5ONFXqW4czPDd6NEizPS=>
UM-UC3MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTN|IH7NNYXESmR4OjR5OES4N|k>
LB831-BLCMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlG4TWM2OD1|NDDuUS=>NFvzT48zPDd6NEizPS=>
KU-19-19MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3Lpb2lEPTB;M{[gcm0>NUH4PHNZOjR5OES4N|k>
35612NGrXc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV30[2ROUUN3ME2zPEBvVQ>?M1n0ZVI1Pzh2OEO5
5637M4L0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofoTWM2OD12NDDuUS=>NWryOldGOjR5OES4N|k>
HT-1197NVTyW5ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYKwUGFXUUN3ME21N{BvVQ>?M3;wTVI1Pzh2OEO5
MGH-U3MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTYTXVKSzVyPUWzJI5ONWfXSYdXOjR5OES4N|k>
TCCSUPNXX1W4d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjuNnBKSzVyPUG0NkBvVQ>?MoSxNlQ4QDR6M{m=
RT4MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnIZYxKSzVyPUG3N|Mhdk1?Mk\4NlQ4QDR6M{m=
SW780NXHtb416T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTN2NUGgcm0>MWOyOFc5PDh|OR?=
RKOMl;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnvZXdPUUN3ME20JI5ONVTmV4NNOjR4OEK3OFc>
LS-411 NMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LPeWlEPTB;NTDuUS=>MmntNlQ3QDJ5NEe=
SW620Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vzTmlEPTB;ODDuUS=>Mn3YNlQ3QDJ5NEe=
HCT-15M2exWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXnTZhWUUN3ME24JI5OMlz4NlQ3QDJ5NEe=
HuTu-80M2LpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\NTWM2OD1zMzDuUS=>NULDZXFXOjR4OEK3OFc>
HCT 116MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTF2IH7NMoHENlQ3QDJ5NEe=
COLO-205NFjHeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfQfWI6UUN3ME2xOEBvVQ>?M4rae|I1Pjh{N{S3
NCI-H747M1jkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTF5IH7NNF;MO3AzPDZ6Mke0Oy=>
COLO-678NYPuT4Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHBTWM2OD1{MTDuUS=>Mn3wNlQ3QDJ5NEe=
LoVoMnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HKPWlEPTB;MkKgcm0>MXeyOFY5Ojd2Nx?=
LS-1034NEn0VJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLxTWM2OD1|MTDuUS=>NInnUYwzPDZ6Mke0Oy=>
SNU-C2BM{mwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLQe2F3UUN3ME20OUBvVQ>?M3PXXVI1Pjh{N{S3
LS-123MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2f4c2lEPTB;N{Ogcm0>NVz6dVVYOjR4OEK3OFc>
SK-CO-1MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHrTWM2OD16MTDuUS=>NGT6b3czPDZ6Mke0Oy=>
HCC2998MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4X6SWlEPTB;MUK4JI5OMkCyNlQ3QDJ5NEe=
MDA-MB-231M{XaOmZ2dmO2aX;uJGF{e2G7MVSxNFAhdk1?NUXKSHY2OzBibXnuM2HYZolvcGmkaYTzJIFk[3WvdXzheIlwdiCxZjDITWYuOc7zMXqyOFI1QDJ4NR?=
MDA-MB-435M1S4cWZ2dmO2aX;uJGF{e2G7NIXDRYsyODBibl2=NHPKeGU{OCCvaX6=MmPhbY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIFjJSk0y|rF?M4\iZ|I1OjR6Mk[1
BT-20 NVTqR2hoTnWwY4Tpc44hSXO|YYm=NIXUUHIyODBxMkWwJI5OMl\INlQhcA>?Mm\udoV{fWy2ZXSgbY4h[SCmb4PlMYRmeGWwZHXueEBl\XO2YXLpcIl7[XSrb36gc4YhTUeIUjygTWdHNUmULDDNSXQtKGGwZDDDVmFHM17KblI1OTd|NUSx
MDA-MB-231M2LxfmZ2dmO2aX;uJGF{e2G7M3zzfVExOCCwTR?=NFy1V|IzPCCqMoLZbY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCjbnSgbY53[XOrdnWgZ4Fx[WOrdIpCpC=>MYmyOFE4OzV2MR?=
H82MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF6ycnVKSzVyPUOwMlI4KG6PNGm5PZczPDF4NkWwOS=>
GLC4NXHjbFRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDjPJdOUUN3ME2yNE41PyCwTR?=Mo\wNlQyPjZ3MEW=
H69MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTh|LkO2JI5ONYT6eGJCOjRzNk[1NFU>
H128NIXkS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVm1Uo5YUUN3ME22PU42PSCwTR?=MmPYNlQyPjZ3MEW=
H146MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjxN|l4UUN3ME2yPE42OSCwTR?=M4TFVVI1OTZ4NUC1
H187M3r5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDBTWM2OD1{ND65PUBvVQ>?MVqyOFE3PjVyNR?=
H526MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXW3TnJnUUN3ME2yNU43PCCwTR?=NEjFdJgzPDF4NkWwOS=>
N592NGnxcJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLaSodKSzVyPUG0MlEzKG6PMXyyOFE3PjVyNR?=
H620MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DPbWlEPTB;M{KuOlchdk1?NUP2Z2N{OjRzNk[1NFU>
H792MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzsN4xPUUN3ME20OU4xPyCwTR?=M1PUTVI1OTZ4NUC1
H1173NEC2V5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXWUopKSzVyPUGyMlYzKG6PNEDr[YkzPDF4NkWwOS=>
AC3NV7XfVRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLOfJNXUUN3ME2yOU46KG6PNXTaPFdJOjRzNk[1NFU>
H82NUSxUWxMTnWwY4Tpc44hSXO|YYm=NHyycVA{OCCwTR?=MUi3NkBpMl3LbY5lfWOnczDw[ZJ{cXO2ZX70JGczN01icHjhd4Uh[XK{ZYP0MYWyOFE3PjVyNR?=
GLC4MnXOSpVv[3Srb36gRZN{[Xl?NXPpOJdGOzBibl2=MVe3NkBpM4HGb4lv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=>NYTHTFhzOjRzNk[1NFU>
H146 NYHWbo5QTnWwY4Tpc44hSXO|YYm=M1XvflMxKG6PNH25dXA4OiCqNV;6e2x1cW6mdXPld{Bx\XK|aYP0[Y51KEd{L12gdIhie2ViYYLy[ZN1NGTUNFQzPDF4NkWwOS=>
OVCAR-5NEP5cI9E\WyuIG\pZYJqdGm2eTDBd5NigQ>?M4K3blAuOTByMDDuUS=>MYO3NkBpMY\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6MmLkNlM6ODBzM{[=
OVCAR-8NVHYWJNDS2WubDDWbYFjcWyrdImgRZN{[Xl?M{GyTFAuOTByMDDuUS=>NWjsbYYzPzJiaB?=NXHPOINEcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=MWmyN|kxODF|Nh?=
A1847MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NWnCcHF{OC1zMECwJI5ONIr2eWY4OiCqM3y4N4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?MUOyN|kxODF|Nh?=
SKOV-3M3HmXWNmdGxiVnnhZoltcXS7IFHzd4F6MXSwMVExODBibl2=MoTkO|IhcA>?NX3lXpl1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=MXOyN|kxODF|Nh?=
OVCAR-5MnL1RZBweHSxc3nzJGF{e2G7M2SyS|ExNTFyMDDuUS=>M1X6RVI1NzR6L{eyJIg>MkS2bY5lfWOnczDhdI9xfG:|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?=MWSyN|kxODF|Nh?=
OVCAR-8MVHBdI9xfG:|aYOgRZN{[Xl?NYPOUI53OTBvMUCwJI5OM{X2VlI1NzR6L{eyJIg>Mln6bY5lfWOnczDhdI9xfG:|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?=MojINlM6ODBzM{[=
A1847NVLPSm5FSXCxcITvd4l{KEG|c3H5MX2xNE0yODBibl2=NV;rTnY5OjRxNEivO|IhcA>?MV\pcoR2[2W|IHHwc5B1d3OrczD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfGy7M4XNeVI{QTByMUO2
H2228MmrFR4VtdCCYaXHibYxqfHliQYPzZZk>NVu4[Yg{OC1zMECwJI5ONV7FPINUPzJiaB?=MVXJR|UxRTF|IH7NNUHSRnJHOjN3M{OyOlU>
H3122MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NUS5UmRVOC1zMECwJI5OMlK2O|IhcA>?NWrBb2FOUUN3ME2xNEBvVQ>?NIf3XpYzOzV|M{K2OS=>
K008M3TPdWNmdGxiVnnhZoltcXS7IFHzd4F6M3yyRWlEPTB;NkCgcm0>M3rncVI{PDF6NUKz
K028NFr6U2RE\WyuIG\pZYJqdGm2eTDBd5NigQ>?MnLQTWM2OD16NDDuUS=>NWjMdGZyOjN2MUi1NlM>
K029NYW3b4lYS2WubDDWbYFjcWyrdImgRZN{[Xl?M4DvTWlEPTB;NE[gcm0>NGHSNVkzOzRzOEWyNy=>
M23NHfPc4NE\WyuIG\pZYJqdGm2eTDBd5NigQ>?NIq1[JZKSzVyPUO3MlUhdk1?NXzuO21COjN2MUi1NlM>
K033MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=>NWKzZ457UUN3ME23OU42KG6PNFL3OWEzOzRzOEWyNy=>
K008M2nt[GZ2dmO2aX;uJGF{e2G7MmHINlUxKG6PNGPZVI4zPCCqMki5bY5lfWOnczDHNkBienKnc4S=M2L2OlI{PDF6NUKz
K028MUfGeY5kfGmxbjDBd5NigQ>?NGLGXoozPTBibl2=M{PubFI1KGh?NVH5XWtTcW6mdXPld{BIOiCjcoLld5Q>M4DhVlI{PDF6NUKz
K029NFTjRmZHfW6ldHnvckBCe3OjeR?=MmX1NlUxKG6PNEHJSWEzPCCqNWLubYZFcW6mdXPld{BIOSCjcoLld5Q>NFLUb4IzOzRzOEWyNy=>
M23NEfCZ|JHfW6ldHnvckBCe3OjeR?=NV\1TFBGOjVyIH7NMoLUNlQhcA>?MojrbY5lfWOnczDHNUBidmRiR{KvUUBienKnc4S=NGHNNYYzOzRzOEWyNy=>
K033MXrGeY5kfGmxbjDBd5NigQ>?MXiyOVAhdk1?NWfjS|BlOjRiaB?=M4XtSIlv\HWlZYOgZUBud2Snc4SgbY5kemWjc3WgbY4hTzFicH;weYxifGmxbh?=Ml3KNlM1OTh3MkO=
K008Ml\uRZBweHSxc3nzJGF{e2G7MoT0NVAxKG6PNV;0OYdwPzJiaB?=MXnzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{MUmyN|QyQDV{Mx?=
K028NFfCOI1CeG:ydH;zbZMhSXO|YYm=NITkRZUyODBibl2=M3:0eFczKGh?NIHESHF{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m|M1n3dlI{PDF6NUKz
K029MYHBdI9xfG:|aYOgRZN{[Xl?MoD0NVAxKG6PMXG3NkBpMnr6d4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>?NI[ze3AzOzRzOEWyNy=>
M23M17KVGFxd3C2b4Ppd{BCe3OjeR?=NIDXSIkyODBibl2=NWrhV4pEPzJiaB?=MkPld4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>?MViyN|QyQDV{Mx?=
K033NFfkTpNCeG:ydH;zbZMhSXO|YYm=MVuxNFAhdk1?MmnqO|IhcA>?M3;QXZNq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN?MmTJNlM1OTh3MkO=
RDM4O1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRThibl2=M2HNNlI{OzB|N{Sx
Rh41M2WzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFm5[ZJKSzVyPUGwMlQhdk1?NWDNeWZlOjN|MEO3OFE>
Rh18MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFWxfnBKSzVyPU[uNkBvVQ>?MnfuNlM{ODN5NEG=
Rh30M4DGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTVwNjDuUS=>MkW3NlM{ODN5NEG=
BT-12M1q4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;ZbGlEPTB;MUSuN{BvVQ>?MoS5NlM{ODN5NEG=
CHLA-266M{HORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTJ5LkGgcm0>NFP4WlkzOzNyM{e0NS=>
TC-71M3HXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV2xTVR3UUN3ME20MlUhdk1?NELWNZEzOzNyM{e0NS=>
CHLA-9NFv6NmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Dic2lEPTB;ND62JI5OMY[yN|MxOzd2MR?=
CHLA-10MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTVwNzDuUS=>MVKyN|MxOzd2MR?=
CHLA-258NFy2SYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoP6TWM2OD14LkSgcm0>NFfleG8zOzNyM{e0NS=>
SJ-GBM2NYrrfJNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTF{Lkmgcm0>NIPWV28zOzNyM{e0NS=>
NB-1643MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;qSGlEPTB;Nz60JI5OMWiyN|MxOzd2MR?=
NB-EBc1NX;RPJlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXWwfXdWUUN3ME2xOk45KG6PM2n5elI{OzB|N{Sx
CHLA-90NEPGVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkm1TWM2OD1{Mj6zJI5ONUXZPYZFOjN|MEO3OFE>
CHLA-136MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfIZnlKSzVyPUKzMlIhdk1?M3vqb|I{OzB|N{Sx
NALM-6MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTFzLkegcm0>MoTTNlM{ODN5NEG=
COG-LL-317NXfVZ5VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnCenhCUUN3ME20MlQhdk1?MYWyN|MxOzd2MR?=
RS4;11Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\k[GlEPTB;MUOuOUBvVQ>?NHnwUJczOzNyM{e0NS=>
MOLT-4NIS2bI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTFyLk[gcm0>MlLxNlM{ODN5NEG=
CCRF-CEM (1)MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTF{LkWgcm0>MXqyN|MxOzd2MR?=
CCRF-CEM (2)NHPlSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHiTWM2OD15LkKgcm0>MVGyN|MxOzd2MR?=
Kasumi-1M{Ht[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\vVGhKSzVyPUWuPEBvVQ>?M3[4[VI{OzB|N{Sx
Karpas-299M{HOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYD4Slg5UUN3ME25MlYhdk1?Ml;4NlM{ODN5NEG=
Ramos-RA1Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTdwNDDuUS=>NXSweIVQOjN|MEO3OFE>
LNCaPM1PuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHMfZIzUUN3ME24JI5ONGTpXoUzOzF3MkCwOC=>
VCaPMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfFN5Z2UUN3ME23JI5ONFG4XFYzOzF3MkCwOC=>
H1355MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLXTWM2OD13IH7NM2P3PVI{ODF{MkS4
H157NV;PSJdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3O4bmlEPTB;NzDuUS=>NH;jcVczOzBzMkK0PC=>
H460MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\ZPGlEPTB;ODDuUS=>NGjxV3AzOzBzMkK0PC=>
IA-LMMoj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3viOmlEPTB;MUCgcm0>NFrn[28zOzBzMkK0PC=>
HOP-62MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTFzIH7NMlXqNlMxOTJ{NEi=
H23MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTFzIH7NNVvwfXlxOjNyMUKyOFg>
H2030NV[xOnFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXL3TJBJUUN3ME2xNkBvVQ>?M4j1bVI{ODF{MkS4
H441M1nYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\lTWM2OD1zNDDuUS=>NX23cnoyOjNyMUKyOFg>
H2212NFqwdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3[4bmlEPTB;MUegcm0>MnHmNlMxOTJ{NEi=
SK-LU-1MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTF6IH7NMl;CNlMxOTJ{NEi=
H2009MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDYTWM2OD1zOTDuUS=>NXewTod6OjNyMUKyOFg>
H1792NHO3XmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjFTWM2OD1{MDDuUS=>MWKyN|AyOjJ2OB?=
COR-L23Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHSfYJKSzVyPUKyJI5ONGrvZm8zOzBzMkK0PC=>
H727MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELpPIdKSzVyPUK4JI5ONHnlWJAzOzBzMkK0PC=>
H1734MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\zWZpjUUN3ME2yPEBvVQ>?NIOzdm8zOzBzMkK0PC=>
H358MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFThcFFKSzVyPUK5JI5OM2rkW|I{ODF{MkS4
A549M2D6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nMZWlEPTB;NEOgcm0>MnT3NlMxOTJ{NEi=
H2122MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\IdHBGUUN3ME21N{BvVQ>?MWOyN|AyOjJ2OB?=
Calu-1NInWTZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTtcYxKSzVyPUW4JI5OMVWyN|AyOjJ2OB?=
Calu-6NFThc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jDemlEPTB;NkSgcm0>NYTPS2dKOjNyMUKyOFg>
NCI-H1975M37LVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TrPVQ5KGh?M3y3fWlEPTB;MU[gcm0>M3npbVIzOTR2Nk[1
NCI-H1975MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLjW3lxPzJiaB?=MY\JR|UxRThibl2=MXuyNlE1PDZ4NR?=

... Click to View More Cell Line Experimental Data

In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]
Features

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines OSA cells
Concentrations 0.001-1μM
Incubation Time 5 days
Method A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.

Animal Study: [4]

Animal Models Female severe combined immune-deficient (SCID) mice
Formulation In DMSO and diluted 1:10 with 20% Cremophor RH 40
Dosages 25 mg/kg/day for 3 days
Administration Tail vein injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] McCleese Jk, et al. Int J Cancer. 2009, 125(12), 2792-2801.

[2] Wang Y, et al. Curr Opin Investig Drugs. 2010 , 11(12), 1466-1476.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02637375 Withdrawn Breast Cancer University of Chicago May 2016 --
NCT02389751 Active, not recruiting Esophageal Cancer M.D. Anderson Cancer Center|Synta Pharmaceuticals Corp. April 2015 Phase 1
NCT02334319 Terminated Stage I Hypopharyngeal Squamous Cell Carcinoma|Stage I Laryngeal Squamous Cell Carcinoma|Stage I Oral Cavity Squamous Cell Carcinoma|Stage I Oropha  ...more Stage I Hypopharyngeal Squamous Cell Carcinoma|Stage I Laryngeal Squamous Cell Carcinoma|Stage I Oral Cavity Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma|Stage II Hypopharyngeal Squamous Cell Carcinoma|Stage II Laryngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma Emory University|Synta Pharmaceuticals Corp. December 2014 Phase 1
NCT02261805 Recruiting Cancer|Small Cell Lung Cancer Georgetown University|Synta Pharmaceuticals Corp. October 2014 Phase 1|Phase 2
NCT02272478 Not yet recruiting Acute Myeloid Leukaemia|Myelodysplastic Syndrome Cardiff University|Cancer Research UK October 2014 Phase 3

view more

Chemical Information

Download Ganetespib (STA-9090) SDF
Molecular Weight (MW) 364.4
Formula

C20H20N4O3

CAS No. 888216-25-9
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 40 mg/mL (109.76 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methyl-1H-indol-5-yl)-2H-1,2,4-triazol-3(4H)-one

Frequently Asked Questions

  • Question 1
    Does this inhibitor inhibit both isoforms of HSP90?

    Answer: We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related HSP (e.g. HSP90) Products

  • PU-H71

    PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.

  • KNK437

    KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.

  • VER155008

    VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.

  • 17-AAG (Tanespimycin)

    17-AAG (Tanespimycin) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

    Features:Displays very low toxicity toward normal cells.

  • Luminespib (AUY-922, NVP-AUY922)

    Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.

  • 17-DMAG (Alvespimycin) HCl

    17-DMAG (Alvespimycin) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

    Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.

  • Geldanamycin

    Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.

  • HSP990 (NVP-HSP990)

    NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

    Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.

  • Elesclomol (STA-4783)

    Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

  • Onalespib (AT13387)

    Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Recently Viewed Items

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us